Synta’s Newest Phase II Results Could Reshape Ganetespib’s Pivotal Data, But Some Analysts Remain Skeptical

Synta provided one-year follow up data for its Phase IIb/III trial testing ganetespib in NSCLC, and revealed some protocol changes which it believes will de-risk the Phase III design. Analysts on the third quarter earnings call by and large bought into the story, but some skepticism remains.

Synta Pharmaceuticals Corp. management delivered an upbeat assessment of one-year follow up data for its Phase IIb/III GALAXY-1 trial testing its lead oncology candidate ganetespib, a heat shock protein 90 (HSP90) inhibitor, in second-line non-small-cell lung cancer.

Although survival data were not as robust as were reported in a June update, most analysts on and off a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D